108 results about "Muscular spasticity" patented technology

The present invention relates generally to muscle relaxation. Muscle relaxation is desired in many disease states, including spastic paresis and biomechanical and neuromuscular dysfunction. More specifically, the invention relates to a system that causes muscle relaxation by reducing muscular spasticity through the stimulation of joints and muscles. The system consists of a garment with electrodes, a hardware unit and software controlling the stimulation.

Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and certain structurally related compounds exhibit clinically significant pharmacological properties which implicate a treatment for a variety of pathological conditions, including spasticity and convulsions, which are ameliorated by effecting a modulation of CNS activity. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.

The present invention relates to compounds of formula I

wherein R¹, R², R³, R⁴, and R⁵ are as defined in the specification. Compounds of the invention are active on the GABAB receptor and are useful for treating a variety of CNS disorders, including anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity-and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastrointestinal disorders.

A wearable maintenance therapy device (10, 12, 14) imparts vibratory stimuli to appendicular muscles of a patient's limb during daily life activity of the patient to reduce symptomatic relapse of spasticity. A vibrator actuator (20) contained in a sup port housing (24) and configured for placement in operational contact with appendicular muscles of a limb (28) of a patient imparts localized vibration to one or more of the patient's appendicular muscles. The localized vibration produces proprioceptive input from the vibrated muscle or muscles (90t) to activate sensory areas of the patient's central nervous system. Programmable electrical control circuitry (50) controls vibration characteristics of the localized vibration and includes memory sites for storing operating values of the vibration characteristics. The vibration characteristics include pattern and timing of vibration specified to produce the proprioceptive input during the patient's daily life activity to mitigate any symptomatic relapse of spasticity.

Methods for treating chronic pain, neuropathic pain or spasticity are provided. Some embodiments are to methods for treatment comprising administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. In some embodiments, administering the cells promotes repair and regeneration of nerves in the patient to decrease chronic pain, neuropathic pain or spasticity. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.

A tolperisone-related compound or a compound of Formula Z is administered for the prevention and treatment of periodic paralyses and myotonias of several types, long QT syndrome, Brugada syndrome, malignant hyperthermia, myasthenia, epilepsy, ataxia, migraine, Alzheimer's Disease, Parkinson's Disease, schizophrenia, and hyperekplexia, neuropathic pain, and pain associated with nervous system disorders including, but not limited to, painful diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, complex regional pain syndrome, Guillain-Barre syndrome (GBS), Charcot-Marie-Tooth (CMT) disease, complex regional pain syndrome, type 1 (CRPS-1), ischemic neuropathy, fibromyalgia, chronic fatigue syndrome, painful spasticities, and other nervous system disorders that have pain as an attendant sign and/or symptom.

New topical medicaments are provided. The medicaments comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA, while the most preferred source of oxygen is a chlorite (e.g., sodium chlorite) and/or spirulina. The medicaments provide high metabolic activities and sustain those activities over prolonged periods of time, thus being useful for treating a large variety of ailments, including diabetic neuropathy, post hepatic neuralgia, scleroderma, psoriasis, strain, spasticity, headaches, neuropathy secondary to drugs, peripheral neuropathy, leg pain, muscle cramps, muscle aches and pains, bruise, sinusitis, sprain, arthritis, joint pain (arthralgia), and edema.

The invention relates to the field of medical instruments and relates to a spasticity evaluation system and device based on the myotatic reflex threshold value and the resistance variable. The device comprises a detection head, a surface electromyogram, a computer and a display screen. The detection head integrates pressure, angle, speed and acceleration sensors and is connected with the computer through a data line or Bluetooth. The surface electromyogram records the electromyographic signals of measured muscles through surface electrodes. The computer analyzes the limb resistance variable, the stretching activity speed and the acceleration generated during a stretching activity and records the joint angle of triggering of myotatic reflex. A linear regression equation of the stretching speed-joint angle of triggering of myotatic reflex is established and the joint angle-myotatic reflex threshold value on the condition of the theoretical stretching speed 0 is obtained. The display screen can display the stretching speed animation preview, the myoelectric activity and the stretching resistance change. The evaluation system and device can solve the problem in accurate evaluation of the upper motor neuron syndrome (UMNS) in rehabilitation medicine, can better perform quantitative evaluation of spasticity therein, and facilitate further selection of reasonable intervention projects.

Described are methods, devices, and systems for a novel, easy to use treatment for spasticity that does not involve medication. Methods and devices herein use low-frequency repetitive magnetic fields to enhance communication in the spinal nerve, thereby allowing improved relaxation, control, and coordination in a muscle.

A medical device known as an implantable infusion device is configured for implanting in humans to deliver a therapeutic substance such as pharmaceutical compositions, genetic materials, and biologics to treat a variety of medical conditions such as pain, spasticity, cancer, and many other conditions. The infusion device incorporates a motor coil connector and mechanical sealing system between the clean motor compartment and the potentially corrosive pump compartment that provides a reliable electrical connection between the motor coil and the motor drive electronics. The motor coil connector provides for bonding of a very small diameter coil wire to one end of the connector and a highly corrosion resistant connection at the other end of the connector. Additionally, the motor coil connector and mechanical sealing system provides a seal against harmful corrosion materials that could emanate from the pump compartment and reach the motor compartment and cause malfunction of the motor. The infusion device has a housing, a power source, a therapeutic substance reservoir, a therapeutic substance pump, and electronics.

The present invention relates to me methods for minimizing spasticity in blood vessels during transplantation and more particularly for minimizing spasticity in arterial transplants, for both ex-vivo and in-vivo procedures. The invention also relates to formulations, which can be used in these methods.

To provide a novel pharmaceutical composition for alleviating pain or spasticity in a patient suffering from spinal cord injury. The present invention relates to a method for alleviating pain or spasticity in a patient suffering from spinal cord injury comprising administering to the patient an effective amount of cGMP PDE5 inhibitor, to a pharmaceutical composition comprising such an effective amount of the inhibitor, and to a use of the inhibitor in the manufacture of such a pharmaceutical composition.